Nonprofit nabs FDA nod for non-prescription naloxone nasal spray

The latest stories trending on MedCity News.

Editor's Pick

Top Story A Non-Profit Pharma Nabs FDA Nod for Non-Prescription Naloxone Nasal Spray The FDA approved RiVive, an over-the-counter version of naloxone nasal spray from Harm Reduction Therapeutics. It's the second such approval from the FDA this year, following an affirmative decision in March for OTC Narcan. Sponsored Content Improve Poor Data Quality Across the Healthcare Ecosystem and Make Workflows More Manageable Presented by IMO Health and MedCity News The webinar, sponsored by Intelligent Medical Objects, will explore the impact of poor data quality and methods to improve patient data quality. It will also highlight healthcare industry employee burnout and how to improve retention. Sign up today and join the discussion!

Featured News

Payer's Place: David Calabrese OptumRx's Chief Clinical Officer shares his insights on the latest developments and trends he's seen in the healthcare industry. 4 ways biopharma is applying AI/ML to improve drug development outcomes Biopharma companies are harnessing AI tools for multiple aspects of drug development such as identifying drug development targets, modeling a drug's effect on the body, and more. How My Brother's Death Changed The Way I Think About Mental Health Care As clinical psychologists, we talk about therapy as the gold standard. I'm not saying it isn't, but if only a minority of people are getting it, we need to broaden our perspective. Hospital Downtime Planning: The Right Strategy & Technology to Ensure Uninterrupted Patient Care It's never a question of whether a hospital will experience downtime — it's a matter of when. Adopting the right downtime technology means hospitals can cut costs, reduce stress on staff and mitigate risk of cyberattack by automatically encrypting data to HIPAA standards. Patients Are More Likely To Get Cancer Screenings Once on Medicare, Report Finds For breast cancer, 20.5% of patients received a screening in the year prior to being on Medicare, compared to 30.4% in the first year of being on Medicare, according to an Epic Research report. For colorectal cancer, screening rates jumped from 6% in the year before being on Medicare to 11% in the first year of being on Medicare.

Resources

MedCity Pivot Podcast: The Toxicity of Immunotherapy In this podcast we hear from Dr. Sumanta Pal, co-director of the City of Hope's Liver Cancer program as a guest after he co-authored an interesting study on immunotherapy that was published in the Lancet. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe